Neurocrine Biosciences, Inc.
USE OF VALBENAZINE FOR TREATING LEVODOPA-INDUCED DYSKINESIA

Abstract:

Provided herein are methods for treating levodopa-induced dyskinesia by administering to a subject (S)-2-amino-3-methyl-butyric acid (2R,3R,11bR)-3-isobutyl-9, 10-dimethoxy-1,3,4,6,7,11b-hexahydro-2H-pyrido[2,1-a]isoquinolin-2-yl ester, or an isotopic variant thereof, or a pharmaceutically acceptable salt or polymorph thereof.